New Research Explores on Anxiety Disorders - Pipeline Review, H2 2016
Anxiety Disorders - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Anxiety Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.
To view the table of contents and know more details please visit Anxiety Disorders - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc Ache Laboratorios Farmaceuticos S/A Adamed Sp. z o.o. Addex Therapeutics Ltd Amorsa Therapeutics Inc. Avineuro Pharmaceuticals, Inc. Azevan Pharmaceuticals, Inc. Biohaven Pharmaceutical Holding Company Limited Bionomics Limited Boehringer Ingelheim GmbH C4X Discovery Holdings PLC Catalyst Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Edgemont Pharmaceuticals, LLC Eisai Co., Ltd. Eli Lilly and Company Fabre-Kramer Pharmaceuticals, Inc. Gabather AB GlaxoSmithKline Plc GW Pharmaceuticals Plc Humanetics Corporation IntelGenx Corp. Intra-Cellular Therapies, Inc. INVENT Pharmaceuticals, Inc. Lead Discovery Center GmbH Marinus Pharmaceuticals, Inc. Merz Pharma GmbH & Co. KgaA Neuralstem, Inc. Neurelis, Inc. NeuroNascent, Inc. Newron Pharmaceuticals S.p.A. Nippon Chemiphar Co., Ltd. Omeros Corporation Otsuka Holdings Co., Ltd. Pherin Pharmaceuticals, Inc. Pragma Therapeutics Protagenic Therapeutics Inc. Suda Ltd Sumitomo Dainippon Pharma Co., Ltd. Synchroneuron Inc. Tonix Pharmaceuticals Holding Corp. Toray Industries, Inc. Trevena, Inc. TRImaran Pharma, Inc. Turing Pharmaceuticals AG
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home